Brokerages Set Lantheus Holdings, Inc. (NASDAQ:LNTH) Price Target at $132.86

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have covered the stock in the last year is $132.86.

Several equities analysts recently commented on LNTH shares. Truist Financial raised their target price on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities restated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. Finally, The Goldman Sachs Group started coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company.

Insider Buying and Selling at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Lantheus

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus during the third quarter worth $25,000. Kestra Investment Management LLC acquired a new stake in shares of Lantheus during the fourth quarter worth $27,000. Summit Securities Group LLC acquired a new stake in shares of Lantheus during the fourth quarter worth $37,000. UMB Bank n.a. grew its stake in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares during the period. Finally, RiverPark Advisors LLC acquired a new stake in shares of Lantheus during the third quarter worth $74,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 6.1 %

Shares of NASDAQ:LNTH opened at $106.34 on Wednesday. Lantheus has a 1-year low of $56.44 and a 1-year high of $126.89. The firm has a market capitalization of $7.28 billion, a PE ratio of 17.69 and a beta of 0.38. The business’s 50 day moving average is $90.71 and its 200-day moving average is $96.82.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. On average, sell-side analysts predict that Lantheus will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.